BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Show more...
執行長
Mr. Roberto Francesco Bellini
員工
40
國家
加拿大
ISIN
CA07987C2040
WKN
000A2PQKK
上市
0 Comments
分享你的想法
FAQ
Bellus Health 今天的股價是多少?▼
BLU.TO 目前價格為 C$19.48 CAD,過去 24 小時下跌了 -0.1%。在圖表上更密切關注 Bellus Health 股票的表現。
Bellus Health 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Bellus Health 的股票以代號 BLU.TO 進行交易。